Evommune, Inc.
EVMN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002044725
In the last 90 days, Evommune, Inc. insiders filed 2 open-market purchases and 0 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $462.5M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Evommune, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +24 vs. Q1 2026
- Shares held
- 34.6M
- +2.19M (+6.7%) vs. Q1 2026
- Total value
- $462.5M
- −$280.8M (−37.8%) vs. Q1 2026
- New holders
- 41
- 36 more added
- Sold out
- 17
- 13 more reduced
3 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVMN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $462.5M |
| Q1 2026 | 84 | $793.4M |
| Q4 2025 | 59 | $465.7M |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Evommune, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nisa Investment Advisors, LLC | 29 | $385 | 0.00% | +29 | New |
| GAMMA Investing LLC | 24 | $319 | 0.00% | +24 | New |
| Fifth Third Bancorp | 21 | $273 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 2 | $27 | 0.00% | +2 | New |
| SRS Capital Advisors, Inc. | 1 | $13 | 0.00% | +1 | New |
| MPM Oncology Impact Management LP | 0 | $0 | 0.00% | −1,455,863−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −879,728−100.0% | Sold out |
| Kynam Capital Management, LP | 0 | $0 | 0.00% | −625,496−100.0% | Sold out |
| Sectoral Asset Management Inc | 0 | $0 | 0.00% | −589,005−100.0% | Sold out |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −448,350−100.0% | Sold out |
| E Fund Management Co., Ltd. | 0 | $0 | 0.00% | −243,700−100.0% | Sold out |
| Integral Health Asset Management, LLC | 0 | $0 | 0.00% | −225,000−100.0% | Sold out |
| StemPoint Capital LP | 0 | $0 | 0.00% | −193,777−100.0% | Sold out |
| Monashee Investment Management LLC | 0 | $0 | 0.00% | −179,340−100.0% | Sold out |
| Octagon Capital Advisors LP | 0 | $0 | 0.00% | −143,472−100.0% | Sold out |
| Propel Bio Management, LLC | 0 | $0 | 0.00% | −55,664−100.0% | Sold out |
| Hudson Bay Capital Management LP | 0 | $0 | 0.00% | −51,364−100.0% | Sold out |
| Palumbo Wealth Management LLC | 0 | $0 | 0.00% | −29,931−100.0% | Sold out |
| China Universal Asset Management Co., Ltd. | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| National Bank of Canada | 0 | $0 | 0.00% | −2,400−100.0% | Sold out |
| STRS Ohio | 0 | $0 | 0.00% | −1,800−100.0% | Sold out |
| Plante Moran Financial Advisors, LLC | 0 | $0 | 0.00% | −1,147−100.0% | Sold out |
| SymBiosis Capital Partners, LLC | – | – | – | – | Not filed |
| Janus Henderson Group PLC | – | – | – | – | Not filed |
| CWM, LLC | – | – | – | – | Not filed |